Frequency of immediate adverse effects associated with apheresis donation

McLeod, Bruce C.; Price, Thomas H.; Owen, H.; Ciavarella, David; Sniecinski, Irena; Randels, M. J.; Smith, James W.

doi:10.1046/j.1537-2995.1998.381098440858.x

Cited by 117 publications

(112 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adverse effects of leukapheresis were evaluated retrospectively until December 1999 and prospectively recorded from January 2000 according to the Hemapheresis Committee of the American Association of Blood Banks questionnaire. 7 Each different course of chemotherapy the patient received before the apheresis was counted as a chemotherapy cycle in Table 1. CD34 + cell determination was performed as previously reported. 6 Two million CD34 + cells/kg body weight (BW) was established as the minimum CD34 + cell dose required, and 5 ϫ 10 6 CD34 + cells/kg BW was considered to be an optimum collection.…”

Section: Methodsmentioning

confidence: 99%

Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients

Sevilla

González‐Vicent

Madero

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:In children, the optimal mobilization schedule for harvesting peripheral blood progenitor cells (PBPC) is an issue of continuous research. We have studied a schedule based on high and daily divided doses of G-CSF (12 g/kg body weight twice daily) for 4 days for PBPC priming. Toxicity related to G-CSF was observed in 13 patients (23%), mainly mild bone pain and myalgia. The median CD34 + cell number collected was 4.4 (0.4-35 ؋ 10 6 /kg body weight), with 46 patients achieving 2 ؋ 10 6 /kg body weight (83.6%) after a single large volume leukapheresis. In conclusion, this mobilization schedule allows safe and efficient collection of the minimum target CD34 + cell dose in most pediatric patients by only one procedure. Bone Marrow Transplantation (2002) 30, 417-420. doi:10.1038/sj.bmt.1703662 Keywords: G-CSF; priming; LVL; children; mobilization In children, peripheral blood progenitor cells (PBPC) are progressively substituting bone marrow as a source of stem cells for hematopoietic transplantation due to their easier collection and faster engraftment. The optimal mobilization schedule for stem cell harvest is a matter of permanent research, since collecting the maximum dose of CD34 + cells is being proposed in order to facilitate subsequent manipulation and shorten granulocyte and platelet engraftment. Although chemotherapy plus growth factors has been reported repeatedly to result in collecting higher numbers of CD34 + cells than G-CSF alone, it has several disadvantages such as a longer mobilization period, chemotherapy toxicity and febrile neutropenia. Moreover, optimal timing of apheresis is not easily scheduled and this hinders optimal progenitor collection especially in patients referred from other regions.In order to improve the progenitor cell collection in our

show abstract

Section: Methodsmentioning

confidence: 99%

Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients

Sevilla

González‐Vicent

Madero

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Many authors have reported the apheresis as a safer procedure which is associated with less frequent adverse donor reactions as compared to whole blood donations [2,3]. A multi-centric study reported the frequency of adverse reactions observed in apheresis donations ranges from 0.32 to 6.81 % [4]. Though these apheresis procedures share a few common adverse events with the whole blood donations (e.g.…”

Section: Introductionmentioning

confidence: 99%

“…), these are associated with few unique adverse events which are not associated with standard phlebotomies and/or whole blood donations [2,3]. These may be attributed to the usage of anticoagulant 'Acid-Citrate-Dextrose' (ACD) causing hypocalcemia and longer donation periods [4].…”

Section: Introductionmentioning

confidence: 99%

Adverse Events During Apheresis Procedures: Audit at a Tertiary Hospital

Dogra

Fulzele

Rout

et al. 2016

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Apheretic platelets are better quality blood components which reduce donor exposure and chances of TTIs to transfusion recipients when compared to the whole blood derived components. Though safe, these apheretic donations are associated with donor adverse events. We evaluated the incidence of such adverse events associated with the modern apheresis procedures that would provide an insight as well as help formulating preventive steps to avoid frequent occurrences of such events. This prospective audit-based observational study was conducted over 1 year. Donors for plateletpheresis were selected as per the standard operating procedure of the Apheresis Lab. The apheresis procedures were done on the MCS? (Haemonetics Corp.), Trima Accel (Terumo BCT) and COM.TEC (Fresenius Kabi AG). 1740 apheresis procedures were performed, out of which 1708 were plateletpheresis and 32 therapeutic plasma exchange (TPE) procedures for 7 patients. A total of 102 adverse events were noted; of which, 80 (78.43 %) events were associated with donors, 15 (14.71 %) were owed to equipment related problems and 7 (6.86 %) were technical aberrations. All the events associated with donors were mild. No adverse events were reported with any of the 32 TPEs. Apheresis procedures are associated with adverse events which can be reduced by meticulous donor-vigilance, superior training modules for the technical personnel and continued supervision of experienced transfusion medicine specialists. Continued efforts towards making the donor's experience with apheresis more pleasant give a forward thrust to the noble vision of preparing a voluntary apheresis donor pool in India.

show abstract

“…The literature suggests that unstimulated leukapheresis product collections are low risk donations. McLeod et al, 7 surveyed centres that had performed nearly 20 000 apheresis procedures. The overall incidence of adverse events was 2.2% with more than half (1.2%) being pain or haematoma at the venipuncture site.…”

Section: Introductionmentioning

confidence: 99%